CA2945707A1 - Dosing regimens for treating and/or preventing cerebral amyloidoses - Google Patents

Dosing regimens for treating and/or preventing cerebral amyloidoses Download PDF

Info

Publication number
CA2945707A1
CA2945707A1 CA2945707A CA2945707A CA2945707A1 CA 2945707 A1 CA2945707 A1 CA 2945707A1 CA 2945707 A CA2945707 A CA 2945707A CA 2945707 A CA2945707 A CA 2945707A CA 2945707 A1 CA2945707 A1 CA 2945707A1
Authority
CA
Canada
Prior art keywords
addnj
period
administering
enzyme
enzyme enhancement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2945707A
Other languages
English (en)
French (fr)
Inventor
Brandon Alan WUSTMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of CA2945707A1 publication Critical patent/CA2945707A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2945707A 2014-04-14 2015-04-14 Dosing regimens for treating and/or preventing cerebral amyloidoses Abandoned CA2945707A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461979408P 2014-04-14 2014-04-14
US61/979,408 2014-04-14
US14/684,967 US9675627B2 (en) 2014-04-14 2015-04-13 Dosing regimens for treating and/or preventing cerebral amyloidoses
US14/684,967 2015-04-13
PCT/US2015/025733 WO2015160796A1 (en) 2014-04-14 2015-04-14 Dosing regimens for treating and/or preventing cerebral amyloidoses

Publications (1)

Publication Number Publication Date
CA2945707A1 true CA2945707A1 (en) 2015-10-22

Family

ID=53015935

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2945707A Abandoned CA2945707A1 (en) 2014-04-14 2015-04-14 Dosing regimens for treating and/or preventing cerebral amyloidoses

Country Status (10)

Country Link
US (2) US9675627B2 (https=)
EP (1) EP3131547A1 (https=)
JP (1) JP6662789B2 (https=)
KR (1) KR20170003576A (https=)
CN (1) CN107148270A (https=)
AU (1) AU2015247859B2 (https=)
CA (1) CA2945707A1 (https=)
HK (1) HK1243643A1 (https=)
SG (1) SG11201610349SA (https=)
WO (1) WO2015160796A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9044437B2 (en) * 2009-10-19 2015-06-02 Amicus Therapeutics, Inc. Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
US9994589B2 (en) 2015-12-14 2018-06-12 Amicus Therapeutics, Inc. Compounds and methods for the treatment of alzheimer's disease and/or cerebral amyloid angiopathy
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
ATE156344T1 (de) 1991-04-25 1997-08-15 Univ Brown Res Found Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
EP1633356A1 (en) 2003-05-22 2006-03-15 The Hospital for Sick Children Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
AU2006254796B2 (en) 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
PL2533050T6 (pl) * 2006-05-16 2016-05-31 Amicus Therapeutics Inc Możliwości leczenia choroby Fabry'ego
WO2007150064A2 (en) 2006-06-23 2007-12-27 Amicus Therapeutics, Inc. METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE
MX2009011473A (es) 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
WO2011011181A1 (en) 2009-07-01 2011-01-27 Amicus Therapeutics, Inc. Pharmacological chaperones for the treatment of alzheimer's disease
US9044437B2 (en) * 2009-10-19 2015-06-02 Amicus Therapeutics, Inc. Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
SG10201604757RA (en) * 2011-03-11 2016-08-30 Amicus Therapeutics Inc Dosing regimens for the treatment of fabry disease
KR102076585B1 (ko) * 2011-12-22 2020-02-12 센토제너 아이피 게엠베하 리소좀 효소를 재배열하는 능력을 갖는 화합물 및 암브록솔 및/또는 암브록솔의 유도체의 조합물
SMT202100136T1 (it) * 2012-05-03 2021-05-07 Amicus Therapeutics Inc Regimi posologici per il trattamento della malattia di pompe

Also Published As

Publication number Publication date
KR20170003576A (ko) 2017-01-09
SG11201610349SA (en) 2017-01-27
US20160008383A1 (en) 2016-01-14
JP6662789B2 (ja) 2020-03-11
AU2015247859A1 (en) 2016-12-01
AU2015247859B2 (en) 2020-03-26
US9675627B2 (en) 2017-06-13
CN107148270A (zh) 2017-09-08
JP2017511372A (ja) 2017-04-20
EP3131547A1 (en) 2017-02-22
US20170273996A1 (en) 2017-09-28
HK1243643A1 (zh) 2018-07-20
WO2015160796A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
EP2490712B1 (en) Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
Bellettato et al. Pathophysiology of neuropathic lysosomal storage disorders
CN103764166B (zh) 蛋白质病的治疗
JP5303458B2 (ja) β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
CN101754682B (zh) 突触核蛋白病的治疗
US20170273996A1 (en) Dosing Regimens for Treating And/Or Preventing Cerebral Amyloidoses
JP6818045B2 (ja) グルコセレブロシダーゼ関連障害を治療するためのアリモクロモル
Shi et al. PGRN as an emerging regulator of lipid metabolism in neurodegenerative diseases
US10519157B2 (en) Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
Kristofikova et al. Inhibitors of acetylcholinesterase derived from 7-methoxytacrine and their effects on the choline transporter CHT1
US20130102538A1 (en) Method of treating alzheimer's disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity
JP6857648B2 (ja) リソソーム障害及び中枢神経系の変性障害の治療及び予防のための（３ｒ，４ｒ，５ｓ）−５−（ジフルオロメチル）ピペリジン−３，４−ジオールを含むレジメン
TW201620517A (zh) 用於治療及／或預防腦澱粉樣變性（Ｃｅｒｅｂｒａｌ Ａｍｙｌｏｉｄｏｓｅｓ）之給藥方案
HK1175400B (en) Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
EP4201403A1 (en) Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses
HK1215534B (en) Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
US20170166588A1 (en) Compounds And Methods For The Treatment Of Alzheimer's Disease And/Or Cerebral Amyloid Angiopathy

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211123